Cam Gallagher Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

Cam Gallagher is President, Interim CFO of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 633,680 shares of ZNTL, which is worth approximately $2.51 Million. The most recent transaction as insider was on May 31, 2024, when has been sold 9,597 shares (Common Stock) at a price of $11.98 per share, resulting in proceeds of $114,972. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 634K

0% 3M change

36.72% 12M change

Total Value Held $2.51 Million

Cam Gallagher Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 31 2024	SELL Open market or private sale	$114,972 $11.98 p/Share	9,597 Reduced 1.49%	633,680 Common Stock
Feb 12 2024	SELL Open market or private sale	$13,419 $11.44 p/Share	1,173 Reduced 0.18%	643,277 Common Stock
Feb 02 2024	SELL Open market or private sale	$133,310 $11.54 p/Share	11,552 Reduced 1.76%	644,450 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	192,500 Added 22.69%	656,002 Common Stock
May 31 2023	SELL Open market or private sale	$730,298 $26.3 p/Share	27,768 Reduced 5.65%	463,502 Common Stock
Feb 14 2023	SELL Open market or private sale	$169,679 $19.96 p/Share	8,501 Reduced 1.7%	491,270 Common Stock
Feb 13 2023	SELL Open market or private sale	$68,039 $20.42 p/Share	3,332 Reduced 0.66%	499,771 Common Stock
Feb 06 2023	SELL Open market or private sale	$226,300 $22.63 p/Share	10,000 Reduced 1.95%	503,103 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	161,092 Added 23.89%	513,103 Common Stock
Jan 17 2023	SELL Open market or private sale	$244,899 $24.49 p/Share	10,000 Reduced 2.76%	352,011 Common Stock
Jan 05 2023	SELL Open market or private sale	$212,399 $21.24 p/Share	10,000 Reduced 2.69%	362,011 Common Stock
Nov 15 2022	SELL Open market or private sale	$288,750 $23.1 p/Share	12,500 Reduced 3.25%	372,011 Common Stock
Nov 08 2022	SELL Open market or private sale	$291,531 $23.56 p/Share	12,374 Reduced 3.12%	384,511 Common Stock
Nov 07 2022	SELL Open market or private sale	$299,375 $23.95 p/Share	12,500 Reduced 3.05%	396,885 Common Stock
Oct 17 2022	SELL Open market or private sale	$293,875 $23.51 p/Share	12,500 Reduced 2.96%	409,385 Common Stock
Oct 06 2022	SELL Open market or private sale	$226,200 $22.62 p/Share	10,000 Reduced 2.32%	421,885 Common Stock
Oct 05 2022	SELL Open market or private sale	$279,750 $22.38 p/Share	12,500 Reduced 2.81%	431,885 Common Stock
Sep 16 2022	SELL Open market or private sale	$246,800 $24.68 p/Share	10,000 Reduced 2.2%	444,385 Common Stock
Sep 15 2022	SELL Open market or private sale	$316,875 $25.35 p/Share	12,500 Reduced 2.68%	454,385 Common Stock
May 30 2022	BUY Grant, award, or other acquisition	-	111,072 Added 19.22%	466,885 Common Stock
Apr 05 2022	SELL Open market or private sale	$511,700 $51.17 p/Share	10,000 Reduced 2.73%	355,813 Common Stock
Mar 15 2022	SELL Open market or private sale	$423,100 $42.31 p/Share	10,000 Reduced 2.66%	365,813 Common Stock
Mar 07 2022	SELL Open market or private sale	$452,300 $45.23 p/Share	10,000 Reduced 2.59%	375,813 Common Stock
Feb 15 2022	SELL Open market or private sale	$520,400 $52.04 p/Share	10,000 Reduced 2.53%	385,813 Common Stock
Feb 14 2022	SELL Open market or private sale	$361,988 $50.36 p/Share	7,188 Reduced 1.78%	395,813 Common Stock

Also insider at

OCUP

Ocuphire Pharma, Inc. Healthcare

Cam Gallagher

President, Interim CFO

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Value

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

Operation

Value

Type

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Track Activities on ZNTL

Account